Bio-Techne Corp. Stock
Bio-Techne Corp. Stock
Bio-Techne Corp. gained 0.830% compared to yesterday.
Bio-Techne Corp. is currently one of the favorites of our community with 8 Buy predictions and no Sell predictions.
As a result the target price of 75 € shows a positive potential of 23.97% compared to the current price of 60.5 € for Bio-Techne Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Bio-Techne Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Bio-Techne Corp. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Cons
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Bio-Techne Corp. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Bio-Techne Corp. | 0.830% | 1.681% | -6.202% | -19.333% | -14.789% | - | - |
Neogen Corp. | 2.700% | 0.885% | -19.149% | -25.974% | -37.705% | -71.139% | -57.518% |
Bio-Rad Labs Inc. A | 2.060% | -2.808% | -21.130% | -38.245% | -13.931% | -51.867% | - |
Merit Medical Systems | - | 0.725% | -0.714% | -5.442% | 2.206% | 34.951% | 41.433% |
Comments
Bio-Techne Co. (NASDAQ: TECH) had its price target lowered by analysts at Stephens from $92.00 to $87.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for TECH provided by MarketBeat
Bio-Techne Co. (NASDAQ: TECH) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $80.00 price target on the stock.
Show more
Ratings data for TECH provided by MarketBeat
Bio-Techne Co. (NASDAQ: TECH) had its price target lowered by analysts at Stifel Nicolaus from $104.00 to $65.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TECH provided by MarketBeat